A combination of three anti-HIV compounds (AZT, ddC and saquinavir) has been studied in vitro. In confirmation and extension of previous studies, a greater than additive effect was found against both HIV-1GB8and HIV-1N1T, when any two compounds were combined. Synergy of action was also found against both virus strains when all three compounds were employed together. Cytotoxicological studies indicated that a high therapeutic index could be maintained for this treatment. The potential benefits of improved anti-HIV surveillance, reduced risk of the development of resistance to the treatment and reduced requirement for drugs in quantities that produce toxic side-effects support the extension of clinical trials of saquinavir to investigate this combination.
No takes yet. Share an insight, caveat, or question.
Craig et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: